THU0642 THERE IS A COMMUNICATION PROBLEM BETWEEN PATIENT AND PHYSICIAN DURING PRE-CONCEPTIONAL PERIOD: HUR-BIO REAL LIFE RESULTS

O
Background: A significant part of patients with inflammatory arthritis are at their reproductive ages. Biological drugs are one of the important treatment options for inflammatory artritis which can cause fetal morbidity and mortality. Management of arthritis during pre-conceptional period is one of the challenges in rheumatology. Objectives: This study aims to assess whether patients under biological treatment share their conception intents with their physicians.
Methods: 1580 patients admitted to our outpatient clinic between July 2015 and July 2016 who were received biological treatment. A questionnaire was performed to 373 patients who are at their reproductive ages. Patients were asked whether they or their wifes had got pregnant after the start of biological agent. If they had got, they were asked; 1. Was the pregnancy intented? 2. Did your physician know if you were going to get pregnant while taking a biological agent? Results: There were total of 79 patients who or whose wifes had got pregnant after the start of biological agent. 34 (%43) out of 79 were female and 45 (%57) out of were male. Mean age of patients were 35.1 (5.3). Median disease duration was 10 (IQR=9) Background: Data capture of patient reported outcomes (PROs) is gradually shifting from data collection on paper in medical office settings to use of computer or mobile based technologies between doctor visits. Concerns have been raised that patients may have limited interest in contributing data over time or that they may only record new data when there has been a change in their clinical status. Objectives: The objective of this study was to evaluate the patterns and factors associated with longitudinal PRO data capture among participants in the PCORIfunded Patient Powered Research Network for adult rheumatologic conditions, ArthritisPower. Methods: Patients in the registry were asked to voluntarily complete PROs including the RAPID3 and 4 PROMIS instruments plus disease-specific information via a mobile application (App) on their smartphone or computer. We evaluated the average time it took the patient to record each of the instruments and the total number of unique days that patients recorded PROs on the smartphone. Given the newness of the registry (launched late 2015), longitudinal data was defined as contributing at least 2 sets of PROs on unique calendar days. We tested the hypothesis that patients would contribute longitudinal data only when at least one of their scores exceeded a minimally important difference (MID) of any of the 5 PROs examined (generally 2-3 units for PROMIS instruments; 3.6 units for RAPID3). Demographic factors associated with multiple PRO reports were identified using logistic regression among patients who had been enrolled in the registry for at least 3 months. Results: At the time of analysis, ArthritisPower had recruited 2,103 patients, most (approximately 68%) had RA, and 20% provided their Twitter handle. Average (SD) age was 50 (12); 87% were women. The mean assessment time for each of the PROMIS instruments ranged from a low of 16 seconds (Sleep Disturbance) to a high of 105 seconds (RAPID3). The average score for Pain Interference was 64.3 (SD: 6.3), Physical Function 37.5 (6.5), Sleep Disturbance 59.3 (8.4), Fatigue 64.2 (8.4), and RAPID3 15.7 (5.3). Of 1,946 patients who registered the Smartphone App more than 3 months prior to analysis, 20.6% never contributed any PRO information, 53.3% answered once, and 26.1% answered at least twice. Among patients with longitudinal data (≥2 assessments), the mean change score of PROs between pairwise PRO assessments was <1 point for all instruments
